Wobble's technology allows patients to accurately understand their cancer status from a single blood test, unlocking better outcomes through earlier diagnosis and improved therapy selection.
Wobble's proprietary RNA technology allows the company to detect hidden and novel isoforms that may be indicative of disease. As a result, Wobble's tests can potentially revolutionise disease discovery and patient outcomes. The technology was developed by Dr Richard Kuo (CEO), a researcher at the University of Edinburgh, in 2021. Richard was also previously a scientist at Columbia University and Caltech following his PhD in Genomics.
